PET is becoming intensively used for the detection of early stages of AD by the visualisation of Abeta accumulation within the brain. However, since accumulations have already occurred and Abeta removing therapies are still not available the need for tools that aid early diagnosis or even allow risk assessment are in desperate need.
We have discovered that the ABC transporters ABCC1 and ABCB1 are major export pumps for toxic peptides from the brain via the blood-brain barrier (BBB) and the blood-choroid plexus barriers (BCPB). It is known that the function of these barriers depend on vascular integrity, age, individual medication, and diets. We investigate the use of Positron-Emission Tomography (PET) for the detection of (early) functional abrogation of the BBB and BCPB that occur before onset of disease symptoms together with our project partners from Austria.
* Project Links:
Read more … PET project link
* Published Research Papers:
Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach
Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET
Journal of Cerebral Blood Flow and Metabolism (2019)
Influence of multidrug resistance-associated proteins on the excretion of the ABCC1 imaging probe 6-bromo-7-[11C]methylpurine in mice
Mol Imaging Biol (2019)
Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice
Journal of Pharmaceutical Sciences (2018)
Factors governing P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier measured with Positron Emission Tomography.
Mol Pharmaceuticals (2015)